Is It Too Late to Invest in Johnson & Johnson After a 48% Surge?

Johnson & Johnson (JNJ) is currently trading at around $225 per share, after gaining 48.6% over the past year, according to data from Simply Wall St. However, the stock has declined 3.8% in the last week and 0.8% over the past month, raising questions about whether most of the gains have already been realized.

Stock Performance

Valuation Assessment

After such a significant rally, investors may wonder if JNJ is still undervalued. At $225, the company's P/E ratio is around 16x, close to the sector average. However, with continued strong cash flows and stable dividends, some analysts believe the stock still has limited upside potential.

Analyst Views

According to recent reports, many analysts still rate the stock as a Buy, with a median price target of $240, implying a potential upside of about 6.7% from current levels. However, some have cautioned that valuation has become less attractive after the recent gains.

Risks and Opportunities

Risks include potential revenue slowdown in the pharmaceutical segment and legal challenges related to talc products. On the positive side, the company has a diversified product portfolio and strength in medical devices, along with a long history of dividend increases.

What This Means for Investors

JNJ appears to have recovered much of its value after the strong performance, but still offers a dividend yield of about 2.8%, making it suitable for income-focused investors. New investors should assess their risk tolerance before making an investment decision, especially given potential short-term market volatility.